BEIJING (Reuters) - Sinovac Biotech Ltd’s coronavirus vaccine candidate CoronaVac was approved for emergency use as part of a programme in China to vaccinate high-risk groups such as medical staff, a person familiar with the matter said.
China National Biotec Group (CNBG), a unit of state-owned pharmaceutical giant China National Pharmaceutical Group (Sinopharm), also said it had obtained emergency use approval for a coronavirus vaccine candidate in social media platform WeChat last Sunday.
CNBG, which has two vaccine candidates in phase 3 clinical trials, did not say which of its vaccines had been cleared for emergency use.
China has been giving experimental coronavirus vaccines to high-risk groups since July, and a health official told state media in an interview aired last week that authorities could consider modestly expanding the emergency use programme to try to prevent possible outbreaks during the autumn and winter.
State media Xinhua reported late on Friday that two vaccine candidates were approved in June for the emergency use program launched in July, without identifying the specific products.
Officially, China has given little details on which vaccine candidates have been given to high-risk people under the emergency use programme and how many people have been vaccinated.
In June, prior to the emergency use programme, employees at state firms travelling overseas were allowed to take one of the two vaccines being developed by CNBG, state media Global Times reported. China’s military had also approved the use of CanSino Biologics’ vaccine candidate.
Seven vaccines against the coronavirus are in final trial stages around the world, and four of them are from China.
But no vaccine has yet passed the final stage of trials proving it is safe and effective - conditions usually required to be met to get regulatory approval for mass use. COVID-19 has killed over 800,000 people worldwide.
Reporting by Roxanne Liu in Beijing and Miyoung Kim in Singapore; Editing by Ana Nicolaci da Costa
Our Standards: The Thomson Reuters Trust Principles.